UnitedHealth Group (NYSE:UNH) reports Q1 2026 results before the market opens on April 21. After one of the most turbulent years in the company’s history, this is the quarter where management either validates its recovery story or forces investors to ask harder questions.
A Year of Damage Control, Now a Year to Deliver
The year-ago quarter set a punishing baseline. In Q1 2025, then-CEO Andrew Witty delivered a miss and slashed the full-year outlook, sending shares down more than 22% on earnings day alone. The stock has never recovered. UNH is down 45.5% over the past year and off 15.36% year-to-date heading into April 21.
The Q4 2025 report brought its own shock. Despite matching the adjusted EPS estimate of $2.11, a $2.88 billion pre-tax charge collapsed GAAP earnings to $0.01 per share. Shares fell 19.61% that day. The charge included $799 million in final cyberattack remediation costs plus sweeping restructuring actions. CEO Stephen Hemsley called it a necessary reset, saying “We confronted challenges directly and finished 2025 as a much stronger company.” The full-year medical care ratio landed at 88.9%, up 340 basis points year-over-year, and operating income fell 41.26% for the full year.
Consensus Estimates for Q1 2026
Metric
Q1 2026 Estimate
Q1 2025 Actual
YoY Change
Adjusted EPS
$6.62
$6.85
-8.1%
Revenue
$110.68B
$109.58B
+1.0%
Full Year 2026 Guidance
Adjusted EPS
Greater than $17.75
vs. $16.35 in 2025
Revenue
Greater than $439B
vs. $447.57B in 2025
The revenue contraction in the full-year guide is intentional. Management is deliberately exiting unprofitable contracts as part of its margin recovery strategy.
MCR Trajectory and Membership Discipline Are the Real Tests
The medical care ratio is the most critical metric to watch. The full-year 2026 guidance targets 88.8% plus or minus 50 basis points, a modest improvement from 88.9% in 2025. But the Q1 2025 MCR was 84.8%, meaning this quarter’s comparison is the easiest of the year. If MCR comes in materially worse than that favorable baseline, the full-year target gets harder to defend.
Membership contraction also deserves close attention. Management guided for a planned exit of 2.3 to 2.8 million members from unprofitable contracts, bringing total UnitedHealthcare enrollment to 46.9 to 47.5 million. The Q1 print will show whether that exit is proceeding in an orderly way or accelerating beyond plan.
Optum Health is the segment that needs the most rehabilitation. Operating earnings collapsed from $2.2 billion to $255 million in Q3 2025 before partially recovering. Management set a Q4 2025 adjusted earnings baseline of approximately $1.5 billion and guided for roughly 9% operating earnings growth in 2026. Whether Q1 tracks that trajectory or shows another deviation will be a key signal for the full-year outlook.
The CFO flagged that slightly under two-thirds of full-year earnings are expected in the first half, driven by Part D benefit changes and business mix. That front-loading makes Q1 a structurally important quarter for the full-year guide to hold.
Active DOJ legal actions concerning Medicare program participation remain an unresolved overhang. Management has not quantified the exposure, and any update on that front will move the stock.
The First Real Test of the Hemsley Reset
This is Hemsley’s first Q1 as CEO, and the first quarter where the restructuring charges and cyberattack costs are fully behind the business. Analysts carry a consensus price target of $357.81 against a current price near $282.33, implying meaningful upside if the recovery story holds. A clean quarter with MCR improvement and stable Optum Health earnings would go a long way toward rebuilding the credibility this stock badly needs.
